Serum miRNA‑204‑5p as a potential non‑invasive biomarker for the diagnosis of endometrial cancer with sentinel lymph node mapping

Wu,Cailiang; Zhou,Xuexin; Li,Jiayong; Xiao,Ruiying; Xin,Haomin; Dai,Lei; Zhu,Yaping; Bao,Wei

doi:10.3892/ol.2022.13368

Serum miRNA‑204‑5p as a potential non‑invasive biomarker for the diagnosis of endometrial cancer with sentinel lymph node mapping

Authors:
- Cailiang Wu
- Xuexin Zhou
- Jiayong Li
- Ruiying Xiao
- Haomin Xin
- Lei Dai
- Yaping Zhu
- Wei Bao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shanghai General Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China, Clinical Laboratory Medicine Center, Shanghai General Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China
Published online on: June 7, 2022 https://doi.org/10.3892/ol.2022.13368
Article Number: 248
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The lymph node status is one of the most critical prognostic factors used in determining adjuvant treatment in endometrial cancer (EC). Lymphadenectomy is associated significant surgical and postoperative risks. The use of sentinel lymph node mapping (SLNM) has emerged as an alternative method to complete lymphadenectomy in EC. However, there remains controversy surrounding the use of SLNM in high‑risk disease and its false‑negative rate (3%). The authors previously identified miR‑204‑5p as a tumor‑suppressor miRNA associated with lymph node metastasis in EC tissues. The present study demonstrated that serum miR‑204‑5p in patients with EC has the potential for use as an early diagnostic biomarker combined with SLNM to assess the lymph node status prior to surgery. The present study also aimed to identify the optimal cut‑off value of serum miR‑204‑5p. The relative expression levels of miR‑204‑5p were detected using reverse transcription‑quantitative PCR in the serum of 52 patients with EC (total SLNM). A total of 20 patients diagnosed with ovarian cysts, 20 patients diagnosed with myoma, and 20 participants diagnosed with endometrial polyps or endometrial hyperplasia were included as the control group. miR‑204‑5p expression was also detected in lymph node tissues using in situ hybridization. The results revealed that serum miR‑204‑5p expression was downregulated in patients with EC compared with its expression in patients with benign ovarian cysts, myoma and endometrial hyperplasia/polyps (P<0.01). In accordance with the final pathological evaluation, patients with EC with a positive SLN status had a significantly lower level of miR‑204‑5p compared with those with a negative SLN status (P<0.01). The area under the ROC curve of miR‑204‑5p was 0.923, 95% CI (0.847‑1.000), and the diagnostic value had a sensitivity of 87.2% and specificity of 80.0%, with an optimal cut‑off value of 0.253. On the whole, it was demonstrated that a lower miR‑204‑5p expression is associated with lymph node metastasis in these SLN(+) EC tissues, indicating that the downregulation of serum miR‑204‑5p in patients with EC has potential for use as an early diagnostic biomarker combined with SLNM. In addition, with a cut‑off value of 0.253, it appeared optimal for the prediction of lymph node metastasis in EC.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Buldukoglu OC, Turker A, Usubutun A and Salman MC: Relationship of lymph node status with survival and recurrence among women with endometrial cancer. Int J Gynaecol Obstet. 151:267–271. 2020. View Article : Google Scholar
3	Li Y, Cong P, Wang P, Peng C, Liu M and Sun G: Risk factors for pelvic lymph node metastasis in endometrial cancer. Arch Gynecol Obstet. 300:1007–1013. 2019. View Article : Google Scholar
4	Suchetha S, Mathew AP, Rema P and Thomas S: Pattern of lymph node metastasis in endometrial cancer: A single institution experience. Indian J Surg Oncol. 12:73–77. 2021. View Article : Google Scholar
5	Frost JA, Webster KE, Bryant A and Morrison J: Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 10:CD0075852017.PubMed/NCBI
6	Accorsi GS, Paiva LL, Schmidt R, Vieira M, Reis R and Andrade C: Sentinel lymph node mapping vs systematic lymphadenectomy for endometrial cancer: Surgical morbidity and lymphatic complications. J Minim Invasive Gynecol. 27:938–945.e2. 2020. View Article : Google Scholar
7	Latif N, Oh J, Brensinger C, Morgan M, Lin LL, Cory L and Ko EM: Lymphadenectomy is associated with an increased risk of postoperative venous thromboembolism in early stage endometrial cancer. Gynecol Oncol. 161:130–134. 2021. View Article : Google Scholar
8	Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016. View Article : Google Scholar
9	Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, et al: Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 16:170–199. 2018. View Article : Google Scholar : PubMed/NCBI
10	Smith AJB, Fader AN and Tanner EJ: Sentinel lymph node assessment in endometrial cancer: A systematic review and meta-analysis. Am J Obstet Gynecol. 216:459–476.e10. 2017. View Article : Google Scholar
11	Tanner EJ, Sinno AK, Stone RL, Levinson KL, Long KC and Fader AN: Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer. Gynecol Oncol. 138:542–547. 2015. View Article : Google Scholar
12	Kataoka F, Susumu N, Yamagami W, Kuwahata M, Takigawa A, Nomura H, Takeuchi H, Nakahara T, Kameyama K and Aoki D: The importance of para-aortic lymph nodes in sentinel lymph node mapping for endometrial cancer by using hysteroscopic radio-isotope tracer injection combined with subserosal dye injection: Prospective study. Gynecol Oncol. 140:400–404. 2016. View Article : Google Scholar
13	Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C, Wang X, Luo Z, Wang J, Liu S, et al: MicroRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer. 19:7382019. View Article : Google Scholar : PubMed/NCBI
14	Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY, Zhang HJ, Wang LH and Wan XP: A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 12:1552013. View Article : Google Scholar : PubMed/NCBI
15	Creasman W: Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009. View Article : Google Scholar
16	Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
17	Cabanas RM: An approach for the treatment of penile carcinoma. Cancer. 39:456–466. 1977. View Article : Google Scholar : PubMed/NCBI
18	Burke TW, Levenback C, Tornos C, Morris M, Wharton JT and Gershenson DM: Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: Results of a pilot study. Gynecol Oncol. 62:169–173. 1996. View Article : Google Scholar
19	Slama J, Dundr P, Dusek L and Cibula D: High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer. Gynecol Oncol. 129:384–388. 2013. View Article : Google Scholar
20	Sonoda K, Yahata H, Okugawa K, Kaneki E, Ohgami T, Yasunaga M, Baba S, Oda Y, Honda H and Kato K: Value of intraoperative cytological and pathological sentinel lymph node diagnosis in fertility-sparing trachelectomy for early-stage cervical cancer. Oncology. 94:92–98. 2018. View Article : Google Scholar : PubMed/NCBI
21	Holloway RW, Ahmad S, Kendrick JE, Bigsby GE, Brudie LA, Ghurani GB, Stavitzski NM, Gise JL, Ingersoll SB and Pepe JW: A prospective cohort study comparing colorimetric and fluorescent imaging for sentinel lymph node mapping in endometrial cancer. Ann Surg Oncol. 24:1972–1979. 2017. View Article : Google Scholar
22	Nagai T, Niikura H, Okamoto S, Nakabayashi K, Matoda M, Utsunomiya H, Nagase S, Watanabe M, Takeshima N and Yaegashi N: A new diagnostic method for rapid detection of lymph node metastases using a one-step nucleic acid amplification (OSNA) assay in endometrial cancer. Ann Surg Oncol. 22:980–986. 2015. View Article : Google Scholar
23	Liu T, Zou XZ, Huang N, Ge XY, Yao MZ, Liu H, Zhang Z and Hu CP: Down-regulation of miR-204 attenuates endothelial-mesenchymal transition by enhancing autophagy in hypoxia-induced pulmonary hypertension. Eur J Pharmacol. 863:1726732019. View Article : Google Scholar
24	Du F, Zhang Y, Xu Q, Teng Y, Tao M, Chen AF and Jiang R: Preeclampsia serum increases CAV1 expression and cell permeability of human renal glomerular endothelial cells via down-regulating miR-199a-5p, miR-199b-5p, miR-204. Placenta. 99:141–151. 2020. View Article : Google Scholar
25	Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, et al: Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 208:534–548. 2011. View Article : Google Scholar
26	Zhang M, Cao M, Kong L, Liu J, Wang Y, Song C, Chen X, Lai M, Fang X, Chen H and Zhang C: miR-204-5p promotes lipid synthesis in mammary epithelial cells by targeting SIRT1. Biochem Biophys Res Commun. 533:1490–1496. 2020. View Article : Google Scholar : PubMed/NCBI
27	He H, Chen K, Wang F, Zhao L, Wan X, Wang L and Mo Z: miR-204-5p promotes the adipogenic differentiation of human adipose-derived mesenchymal stem cells by modulating DVL3 expression and suppressing Wnt/β-catenin signaling. Int J Mol Med. 35:1587–1595. 2015. View Article : Google Scholar : PubMed/NCBI
28	Xu G, Chen J, Jing G and Shalev A: Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med. 19:1141–1146. 2013. View Article : Google Scholar : PubMed/NCBI
29	Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva WA Jr, Falcao RP and Zago MA: miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 40:1435–1440. 2007. View Article : Google Scholar : PubMed/NCBI
30	Yuan X, Wang S, Liu M, Lu Z, Zhan Y, Wang W and Xu AM: Histological and pathological assessment of miR-204 and SOX4 levels in gastric cancer patients. Biomed Res Int. 2017:68946752017. View Article : Google Scholar
31	Li Y, Chen R, Li Z, Cheng H, Li X, Li T and Zhu C: MiR-204 negatively regulates cell growth and metastasis by targeting ROBO4 in human bladder cancer. Onco Targets Ther. 12:8515–8524. 2019. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Xing L, Xu H, Wang K, She J, Shi F, Wu H, Sun Y, Gao J and He S: miR-204-5p suppress lymph node metastasis via regulating CXCL12 and CXCR4 in gastric cancer. J Cancer. 11:3199–3206. 2020. View Article : Google Scholar : PubMed/NCBI
33	Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, et al: Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 107:326–334. 2016. View Article : Google Scholar
34	Zou Y, Jing C, Liu L and Wang T: Serum microRNA-135a as a diagnostic biomarker in non-small cell lung cancer. Medicine (Baltimore). 98:e178142019. View Article : Google Scholar : PubMed/NCBI
35	Schneider R, McKeever P, Kim T, Graff C, van Swieten JC, Karydas A, Boxer A, Rosen H, Miller BL, Laforce R Jr, et al: Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study. J Neurol Neurosurg Psychiatry. 89:851–858. 2018. View Article : Google Scholar : PubMed/NCBI